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Transmembrane helical proteins are underrepresented in the PDB due to the experimental difficulties associated with their protein expression and crystallisation. This results in a small pool of structures being available for conventional homology-based Molecular Replacement (MR) and places a premium on the development of unconventional homology-independent approaches.
AMPLE is a pipeline for using unconventional models in automated MR. It has been particularly successful in its cluster and truncate approach to creating search ensembles from ab initio molecular models [1] . Recent work has focussed on exploring the viability of different approaches to the clustering and truncation. By exploring multiple clusters and using TM scoring, we have been able to double the success rate of AMPLE on a difficult set of test cases without an increase in processing time.
Using the new approach, and combining it with intermolecular contact prediction [2] to improve the modelling, we have been exploring the effectiveness of AMPLE on a selection of alpha-helical transmembrane proteins. Our work has demonstrated that AMPLE is a powerful method to use on this class of protein, outperforming a baseline approach based on short alpha-helices, and able to solve the majority of cases in our test set with an average runtime of less than two days on a single processor. Binding of a clinically used antagonist, vismodegib, to the TMD induces a conformational change that is propagated to the CRD, resulting in loss of cholesterol from the CRD-LD-TMD interface. Our work elucidates the structural mechanism by which the activity of a GPCR is controlled by ligand-regulated interactions between its extracellular and transmembrane domains.
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